• 1
    Arcasoy SM, Kotloff RM. Lung Transplantation. N Engl J Med 1999; 340: 10811091.DOI: 10.1056/NEJM199904083401406
  • 2
    Heng D, Sharples L, McNeil K, Stewart S, Wreghitt T, Wollwork J. Bronchiolitis obliterans syndrome. Incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17: 12551265.
  • 3
    Jackson JH, Sharples DL, McNeil K, Stewart S, Wallwork J. Acut and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities. J Heart Lung Transplant 2002; 21: 658666.DOI: 10.1016/S1053-2498(02)00381-9
  • 4
    Girgis RE, Tu I, Berry GJ et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J heart Lung Transplant 1996; 15: 12001208.
  • 5
    Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 413.
  • 6
    El-Gamel A, Sim E, Hasleton P et al. Transforming growth factor beta (TGF-B) and obliterative bronchiolithis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828837.DOI: 10.1016/S1053-2498(99)00047-9
  • 7
    Sharples DL, MC Neil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systemic review of recent publications. J Heart Lung Transplant 2002; 21: 271281.DOI: 10.1016/S1053-2498(01)00360-6
  • 8
    Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297310.DOI: 10.1016/S1053-2498(02)00398-4
  • 9
    Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7: 120125.
  • 10
    Beeh KM, Beier J, Kornmann O, Micke P, Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. J Heart Lung Transplant 2001; 20: 11441151.
  • 11
    Yousem SA, Berry GJ, Cagle PT et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996; 15: 115.
  • 12
    Aharinejad S, Taghavi S, Klepetko W, Abraham D. Prediction of lung-tranplant rejection by hepatocyte growth factor. Lancet 2004; 363: 15031508.DOI: 10.1016/S0140-6736(04)16148-5
  • 13
    Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med 2000; 6: 133139.
  • 14
    Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001; 2: 1019.DOI: 10.1186/rr33
  • 15
    Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117: 684694.
  • 16
    Hayashi T, Stetler-Stevenson WG, Fleming MV et al. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol 1996; 149: 12411256.
  • 17
    Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL 2nd, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458464.
  • 18
    Devouassoux G, Drouet C, Pin I et al. for the Grenoble Lung Transplant Group. Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, and increases with degree of severity. Transpl Immunol 2002; 10: 303310.DOI: 10.1016/S0966-3274(02)00074-6
  • 19
    Corbel M, Boichot E, Lagente V. Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz J Med Biol Res 2000; 33: 749754.
  • 20
    Herget J, Novotna J, Bibova J, Povysilova V, Vankova M, Hampl V. Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2003; 285: L199L208.